Raymond James Financial Inc. acquired a new stake in Bruker Co. (NASDAQ:BRKR - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,268 shares of the medical research company's stock, valued at approximately $661,000.
A number of other institutional investors have also recently added to or reduced their stakes in BRKR. Eagle Bay Advisors LLC grew its position in shares of Bruker by 2,324.1% in the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company's stock valued at $41,000 after purchasing an additional 674 shares during the last quarter. UMB Bank n.a. increased its position in Bruker by 37.5% during the fourth quarter. UMB Bank n.a. now owns 909 shares of the medical research company's stock worth $53,000 after buying an additional 248 shares in the last quarter. GAMMA Investing LLC lifted its position in shares of Bruker by 47.5% in the fourth quarter. GAMMA Investing LLC now owns 1,279 shares of the medical research company's stock valued at $75,000 after acquiring an additional 412 shares in the last quarter. Quadrant Capital Group LLC raised its stake in Bruker by 18.2% in the 4th quarter. Quadrant Capital Group LLC now owns 1,273 shares of the medical research company's stock valued at $75,000 after purchasing an additional 196 shares during the last quarter. Finally, EverSource Wealth Advisors LLC boosted its stake in shares of Bruker by 41.5% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,330 shares of the medical research company's stock worth $78,000 after purchasing an additional 390 shares during the last quarter. Hedge funds and other institutional investors own 79.52% of the company's stock.
Bruker Price Performance
Shares of BRKR traded down $2.72 during mid-day trading on Friday, hitting $37.79. The company's stock had a trading volume of 4,239,535 shares, compared to its average volume of 1,566,338. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The stock has a market capitalization of $5.73 billion, a price-to-earnings ratio of 49.72, a PEG ratio of 2.16 and a beta of 1.23. The firm has a 50-day moving average price of $41.26 and a 200 day moving average price of $51.15. Bruker Co. has a fifty-two week low of $34.10 and a fifty-two week high of $79.78.
Bruker (NASDAQ:BRKR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical research company reported $0.47 earnings per share for the quarter, beating analysts' consensus estimates of $0.46 by $0.01. The company had revenue of $801.40 million for the quarter, compared to the consensus estimate of $763.83 million. Bruker had a return on equity of 21.01% and a net margin of 3.36%. The firm's quarterly revenue was up 11.0% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.53 EPS. On average, research analysts predict that Bruker Co. will post 2.69 EPS for the current fiscal year.
Bruker Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Monday, March 17th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.53%. Bruker's dividend payout ratio (DPR) is presently 26.32%.
Analyst Ratings Changes
A number of analysts recently issued reports on BRKR shares. UBS Group decreased their target price on shares of Bruker from $57.00 to $45.00 and set a "neutral" rating on the stock in a research report on Thursday. Wells Fargo & Company lowered their price objective on shares of Bruker from $75.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, April 17th. The Goldman Sachs Group reduced their price objective on Bruker from $50.00 to $45.00 and set a "neutral" rating on the stock in a research note on Thursday. Guggenheim reaffirmed a "buy" rating on shares of Bruker in a report on Monday, February 24th. Finally, Stifel Nicolaus dropped their price objective on Bruker from $57.00 to $48.00 and set a "hold" rating on the stock in a report on Thursday. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $60.10.
Check Out Our Latest Stock Analysis on BRKR
Bruker Profile
(
Free Report)
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.
Recommended Stories
Before you consider Bruker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bruker wasn't on the list.
While Bruker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
